P388 LEUKEMIA-CELLS RESISTANT TO THE ANTHRACYCLINE MENOGARIL LACK MULTIDRUG RESISTANT PHENOTYPE

被引:8
作者
BADINER, GJ [1 ]
MOY, BC [1 ]
SMITH, KS [1 ]
TARPLEY, WG [1 ]
GROPPI, VE [1 ]
BHUYAN, BK [1 ]
机构
[1] UPJOHN CO,CELL BIOL,CANC & INFECT DIS RES,KALAMAZOO,MI 49001
关键词
D O I
10.1038/bjc.1990.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Menogaril is an anthracycline presently in Phase II clinical trials. Menogaril-resistant mouse leukaemia P388 cells were developed in vitro by 4 months of exposure to step-wise increasing concentrations of menogaril after which resistant cells (P388/MEN) were cloned in 320 ng ml-1 menogaril. P388/MEN cells were 40-fold more resistant to menogaril in vitro compared to P388/0 and were also resistant in vivo. Resistance to menogaril was stable for at least 2 months in the absence of the drug. The results indicate that P388/MEN, although resistant to an anthracycline, did not dispay the typical multidrug resistant phenotype. It was not cross-resistant to several structurally unrelated drugs such as actinomycin D, cisplatin, or vinblastine, but it was cross-resistant to the anthracycline, adriamycin. Uptake and efflux of menogaril was similar in sensitive and resistant cell lines. Also, resistance was not reversed by verapamil. No major karyotypic difference was noted between P388/0 and P388/MEN. There was no significant amplification or overexpression of the mdr gene in P388/MEN compared to P388/0. In contrast to P388/MEN, P388 cells resistant to adriamycin displayed the typical multidrug resistant phenotype. Glutathione content of P388/MEN cells was similar to that of P388/0 and depletion of glutathione did not potentiate menogaril cytotoxicity. Therefore, we conclude that glutathione is not likely to be involved in menogaril resistance to P388/MEN cells. © Macmillan Press Ltd., 1990.
引用
收藏
页码:378 / 384
页数:7
相关论文
共 40 条
  • [1] BADINER GJ, 1987, P AM ASSOC CANC RES, V28, P299
  • [2] BADINER GJ, 1987, P AM ASSOC CANC RES, V28, P281
  • [3] BADINER GJ, 1986, P AM ASSOC CANC RES, V27, P265
  • [4] BADINER GJ, 1987, INVEST NEW DRUG, V5, P219
  • [5] BADINER GJ, 1986, J CELL BIOL, V10, pA28
  • [6] PLEIOTROPIC PHENOTYPE OF COLCHICINE-RESISTANT CHO CELLS - CROSS-RESISTANCE AND COLLATERAL SENSITIVITY
    BECHHANSEN, NT
    TILL, JE
    LING, V
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1976, 88 (01) : 23 - 31
  • [7] BERAN M, 1987, CANCER RES, V47, P1897
  • [8] BHUYAN BK, 1980, CANCER RES, V40, P3437
  • [9] ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE
    CHIRGWIN, JM
    PRZYBYLA, AE
    MACDONALD, RJ
    RUTTER, WJ
    [J]. BIOCHEMISTRY, 1979, 18 (24) : 5294 - 5299
  • [10] DANKS MK, 1987, CANCER RES, V47, P1297